| Abstrakt: |
BOSTON, May 9, 2024 /PRNewswire/ -- Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer, will be presenting at the 2024 Guggenheim Healthcare Talks Radiopharmaceuticals Day, being held Monday, May 13, 2024, in New York City. Dr. Roden will participate in a fireside chat at 1:30 p.m. ET and a panel titled, "The Evolving Landscape of Radiopharmaceuticals in Industry - Considerations for Innovation and Pharma Engagement," at 12:00 p.m. ET. [ABSTRACT FROM PUBLISHER] |
